Neurology/Psychiatric ATH-1105 protects from TDP-43 protein pathology in preclinical models July 21, 2023 There is a strong link between the loss of TAR DNA-binding protein 43 (TDP-43) function and the development of frontotemporal dementia (FTD)...Read More
Neurology/Psychiatric ATH-1105 protects against disease progression and delays time to mortality in mouse model of ALS April 28, 2023 Researchers from Athira Pharma Inc. presented preclinical efficacy data for ATH-1105, a positive modulator of hepatocyte growth factor (HGF)/MET, being evaluate for the treatment of amyotrophic lateral sclerosis (ALS).Read More
Neurology/Psychiatric Athira eyes IND filing this year for ATH-1105 for ALS Jan. 9, 2023 Athira Pharma Inc. is advancing ATH-1105 toward a planned IND filing this year for first-in-human studies for amyotrophic lateral sclerosis (ALS).Read More
